Cytrellis Biosystems

Cytrellis Biosystems, Inc. (operating as Cytrellis, Inc.) is a medical technology company focused on the development and commercialization of aesthetic devices. Its first product, ellacor, is a system based on proprietary Micro-Coring Technology that removes sagging skin at the micro-scale, intended to address age-related skin changes without the use of energy, surgery, or scarring. The company positions ellacor as a tool for aesthetic practitioners, including dermatologists and plastic surgeons, to treat facial skin laxity and wrinkles.

The ellacor System with Micro-Coring Technology received FDA clearance for use by medical professionals to treat moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Following clearance, the company pursued an initial commercial rollout with a small group of key physicians, with a full national rollout anticipated in 2022. In January 2025, Cytrellis announced an updated next-generation version of the treatment, ellacor 2.0, which it described as supported by new leadership and financing.

The company describes itself as a Massachusetts-based, venture capital backed business, and maintains an active hiring program in the U.S., stating that applicants must already be authorized to work for any U.S. employer.

Business model

Cytrellis develops and commercializes proprietary aesthetic medical devices, selling systems and treatments to aesthetic practitioners such as dermatologists and plastic surgeons. Series C proceeds were directed toward building commercial infrastructure, clinical research, product development and manufacturing.

Traction

Reported a solid foundation of robust clinical data at the time of its 2021 Series C, FDA clearance of the ellacor system, and a subsequent next-generation product launch in January 2025. The company states it is growing and actively recruiting.

Latest developments

On January 7, 2025, Cytrellis announced the launch of the updated next-generation skin removal treatment ellacor 2.0, attributed to new leadership and new financing. The leadership team is led by President and CEO Denise Dajles, PhD, with Oliver Bennett as Chief Business Officer and General Counsel, Bob Hinz as VP Operations, and Karyn Siemasko, PhD as VP Medical Affairs; the board is chaired by John McDonough and includes Keith L. Crandell, Nilay Thakar, Chris Minton and Denise Dajles. Karen Cronholm was President and CEO at the time of the 2021 Series C.